US FDA requests removal of suicide warnings from weight-loss drugs

The U.S. health regulator on Tuesday asked drugmakers to remove label warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, including Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The request, also covering Novo’s older weight-loss drug Saxenda, follows a...

Redirecting to full article...